We developed a new cytochemical assay for identification of cells containing inosine monophosphate dehydrogenase (IMPDH) and measurement of tumor cell sensitivity to the escalating doselschedule of the IMPDH pattern-targeting drugs. The assay is based on cytochemical principles for development of DH activity markers inside morphologically classified cells, image analysis for measuring the amount of this marker, and computer assistance for data management. The assay was optimized on a human leukemia cell line (K562-NS) and reference values for enzyme activity were established. Assay specificity was determined with different substrates and enzyme inhibitors. Sensitivity depends on the measuring instrument (image analyzing system), and the precision of the biological model used for assessment of refer-ence values was high. IMPDH-positive malignant cells were found in all specimens obtained from acute leukemia and solid tumor patients (13113 and 29/29) and in four human tumor cell lines (K562, K562-NS, W O , andHL60-M). Cells of the K562-NS line were exposed to tiazofurin and ribavirin in conventional assays for assessment of drug-induced acute and subacute toxicity/sensitivity. A reduction of IMPDH activity was recorded at drug concentrations below the range at which cell damage appeared. ( J Hisrochem Cytochem
Introduction
Inosine 5'-monophosphate dehydrogenase (1MP:NAD oxidoreductase, IMPDH; EC 1.1.1.205) is the rate-limiting enzyme of de novo guanosine 3-phosphate (GTP) biosynthesis. IMPDH converts inosine monophosphate (IMP) to xanthosine monophosphate (XMP), which is subsequently converted to guanosine phosphates and enters the nucleic acid pool. Inhibition of this enzyme may send a negative signal to the nucleus, inducing an antiproliferative effect. Increased IMPDH activity was found in highly proliferative cells, whereas a decrease was inversely related to differentiation and maturation of the same cell types (1-4). The increased activity of IMPDH in cancer cells suggests that the enzyme may be a sensitive target for chemotherapy designed to kill or to alter the behavior of malig-42:23- 35, 1994) nant cells (5,6). At least two nucleoside analogues targeting IMPDH have been recently recognized: tiazofurin as an anti-leukemic and ribavirin as an anti-viral agent (7-9).
The possibility of treating cancer patients by chemical induction of the differentiation and maturation of malignant cells is a challenging task. Inspired by reports favoring this aspect of cancer chemotherapy, we have searched for an assay that would assist physicians in appropriate selection of patients for clinical trials with selected IMPDH-targeting drugs, to avoid otherwise necessary disappointment with therapy failures. Surprisingly, methods currently available are based on biochemical analysis of tissue homogenates (10) (11) (12) (13) (14) .
Information about the comparison of tumor specimens, concerning the amount of tumor parenchymal tissue and its relation to stromal and normal tissue elements within the tumor, can be obtained only by histo(cyto)logical methods. Likewise, enzyme activity in single classified cells can be obtained only by cytochemical techniques. Similar methods are required to select patients with populations of malignant cells sensitive to the IMPDH-targeting drugs.
The assay consists of three steps. The first step is to prepare an appropriate specimen: a smear of individual cells on microscopic slide. The second is to visualize a marker for intracellular IMPD activity (cytochemical reaction). The third step is to measure the amount of this marker, i.e., IMPDH activity in a population of a certain cell type. Image analysis assistance is an important advantage for accuracy and reproducibility of measurement. The IMPDH assay flow chart (Figure 1 ) covers the most important steps of this method.
CTRL, INHIBITORS IN SITL
Malignant cells are available as established human tumor cell lines or can be obtained from bone marrowlperipheral blood (hematologic malignancy), other body fluids (exfoliative cytology), and from surgical biopsy specimens. To illustrate the applicability of the assay we have used all these specimens ( Figure 1 ) and, in a setting of assays for assessment of drug sensitivityltoxicity, have exposed malignant cells to the IMPDH-inhibiting drugs.
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Specimen Preparation
For assessment of IMPDH activity in cells, the analytical specimens should be amenable to morphological classification, cytochemical reaction, and image analysis. We found that only monolayers of single cells are satisfactory specimens. Therefore, cell suspensions (blood, cerebrospinal fluid; exudates: ascites, pleural effusions; and cell lines growing in suspension) must be smeared (manually or by cytospin centrifuge) on microscope slides. Cell cultures growing on matrices must be allowed to grow as monolayers on slides (chamber-slide techniques) (LabTech, Naperville, IL). Imprints of solid tumor tissue, made by a technique usually used for cytological exami- nation, are less adequate for IMPDH assay because of the requirements for image analysis. We use an imprintkmearing technique that, owing to different cohesiveness among tumor, stromal, and normal cells, provides a greater than 95% pure population of cancer cells on the slide (15). Thinneedle biopsy material must be suspended in cell culture growth medium. Primary tumor cell cultures obtained from biopsy material can also be used in this assay. For assay development, we prepared analytical specimens using the K562 cell line, particularly its clone K562-NS, and both HL60 immature and mature clones. All four cell lines grow in suspension (16). To study IMPDH disuibution. we used peripheral blood smears from patients with acute leukemia, bronchial washings obtained from patients with bronchogenic carcinoma, and surgical biopsy specimens from patients with solid tumors. To study the effects of IMPDH-targeting drugs, we used smears of K562-NS cell line cells.
We ran the experiments with two internal controls: one without IMP substrate (CTRL1) to demonstrate NSA and establish a threshold of detection for the specific activity of IMPDH; and another one, without NBT (C"RI/2), to detect eventual color deposits not related to formazan (Figure 1 ).
TEST incubation mixture contains all components, CTRL1 mixture lacks IMP, and CTRL-2 does not contain NBT. Details about the composition of the incubation mixture (e.g., concentrations of ingredients, buffer) are patent-protected (US patent pending). A research kit containing TEST, CTRL1, and CTRL2 reagents is available from the authors until the end of 1994.
As a result of incubation with TEST, a dark-blue granular deposit of formazan precipitate appeared at sites of the enzyme activity and marked the IMPDH-positive cells (TDA including the specific IMPDH) ( Figure 2 ). Incubation with CTRL1 produced a lesser amount of formazan and marked NSA positivity. CTRL2 did not produce any formazan deposit inside cells.
Cell Classz3cation
Counterstaining and Parallel Staining Classic morphology is sufficient for identification and classification of cells obtained from patients (17) (18) (19) . Cells were characterized according to their morphologic integrity, mitotic stage, subcellular organelles, and conventional signs of cell destruction. Additional criteria were used for assessment of drug-induced cell damage and cell maturation. Distinct morphological criteria for the identification of drug-induced cell damage include the following: swelling of nuclei and/or cytoplasm, acidophilia (change of color to red), any fragmentation of nuclei and major fragmentation of cytoplasm, vacuolization in both cytoplasm and nuclei, and degree of nuclear indentation.
Both parent cell lines, K562 and HL60, undergo spontaneous maturation under certain conditions. K562 may mature into an erythroblastic cell type, K562-NS into myeloid, and HL6O-M is a clone with myeloid differentiation of HL60 (4,20,21). As prominent features of erythroblastic maturation, we have considered the change of cytoplasmic staining from dark blue to pink and red. Any appearance of azurophilic granules in the cytoplasm andlor nuclear changes such as elongation, polylobulation, or polymorphism was considered to represent the granulocytic/monqtic type of maturation.
Fimtion
Specimens for IMPDH assay were air-dried for 5 min. We do not recommend the use of chemical fixatives, as IMPDH is a very sensitive enzyme. Counterstaining does not require post-fixation.
Specimens for morphological classification were air-dried at room temperature (RT) for at least 2 hr. fixed in methyl alcohol for 3 min. and subsequently stained with Wright stain or the May-Griinwald-Giemsa (MGG) technique.
Incubation and Cytochemical Fimtion
We assumed that ifa nonspecific dehydrogenase (DH) activity, always present in live cells, could be visualized by a general cytochemical DH reaction, then the addition of IMP substrate to the incubation mixture should uncover the specific IMPDH activity. This allows distinction between total dehydrogenase activity (TDA). specific IMPDH activity (IMPDH), and nonspecific IMPDH activity (NSA).
To demonstrate TDA within single cells we exposed cell specimens for 60 min at 37°C to an incubation mixture containing inosine-5'monophosphate (IMP) as a specific substrate, nicotine amide dinucleotide (NAD) as the enzyme co-factor, phenazinemethosulfate (PMS) as an electron acceptor, and nitroblue tetrazolium salt (NBT). This was our "TEST" incubation mixture.
After the cytochemical reaction we counterstained the slides with safranin 0 (red stain for nuclei with maximal absorption at 530 nm) or hematoxylin (Harris) (brownish stain for nuclei and cytoplasmic granules) to visualize morphological characteristics necessary for cell classification (22) (23) (24) .
Separately, slides were stained with MGG to provide morphological criteria for conventional cytological classification (17) (18) (19) . It is necessary to perform MGG staining before the IMPDH assay, to provide the cytologist with distinct morphological criteria to identlfy malignant cells on an image analyzer's monitor during measurement of IMPDH activity and to dassl fy them in real time (Figure 1 ).
Evaluation
This assay can be evaluated with and without image analysis assistance. The following endpoints were used for evaluation.
Subjective Estimate (Without Image Analysis) Semiquantitative Parameters
Percentage of Positive Cells and of Positive Malienant Cells. Using counterstained slides, a morphologist identifies cells and classifies them into cell type groups, and records the IMPDH positivity as present (+) or absent (-). Percentage of positive cells (%C) denotes the frequency of positivity in a cell classification group or in specimens of monoclonally derived cell lines. Another parameter is the percentage of positive malignant cells (%MC') in smears with more than one type of cells ( Figure 1 ).
Mean Score. For those without image analysis facilities, we recommend the calculation of mean score (MS), which is a semiquantitative and subjective but reliable parameter. It is based on the estimation of the relative degree of formazan formation per cell ('Czble 1).
Estimating at least 200 cells, we calculated MS as an arbitrary index of mean IMPDH activity per cell representing the selected cell type, using the following formula:
where Z stands for the sum, D' is the value of each degree, and P is each percentage of cells at a degree (Table 1) .
Objectiw Assessment (image analysis-assisted). We used Imagescan software (Carl Zeiss; Thornwood, NY), version 1985, as the breadboard (Fig   ure 3) . The system defines features to be measured inside an imaginary space outlined by two cursors on a gray-level scale from 0 to 255 (Z-axis) and separated from other features on the plane binary image (Xsaxis) by a variable frame projected on the microscope monitor screen. Using this variable frame, an operator selects images of single cells from other cells in the microscopic field and segments them into two features: the intracellular formazan precipitate (FRP), and the entire cell (CELL). The instrument measures FRP and CELL by two optical parameters: area (A) and optical density (OD). A is defined as the number of picture points inside a binary image region outlined by a feature perimeter (boundaries projected as the variable frame). OD is defined as the mean optical density per unit of area. Both have been calibrated: A in pm2, OD in optical density units (from 0.0 to 1.0). OD has been calculated as -log (transmitted/incident light) obtained from a detected feature vs the number of units of area of the same feature (16, 21, (23) (24) (25) (26) (27) (28) .
A population analysis requires a sample unit of at least 25 cells of a given cell type. A morphologist selects these cells on 'EST, CTRLl, and CTRL2 slides. Imagescan measures A and OD of FRP and CELL from the image of each cell and saves the data for calculation. The enzyme unit is an arbitrary measure of IMPDH activity. One EU is defined as the activity of IMPDH per single cell that is able to reduce IMP substrate in the presence of NAD, PMS, and NBT, producing a formazan deposit of twice the amount obtainable by nonspecific cell reducing capacity (incubation mixture without IMP) during 60 min at 37'C.
Reliability of the Assay
We have measured the precision, sensitivity, and specificity of our assay. These parameters were measured on a K562 parent and a K562-NS cell line model and on two HL60 cell line clones: conventional (HL60) and mature (HLCO-M). All four cell lines contain IMPDH but in different amounts (Eble 2). The least amount was detected in the HL60-M cell line and the greatest in the HL60 cell line.
Precision refers to the agreement between replicate measurements. We measured within-run precision with different image analyzers: Imagexan (Carl Zeiss), SMI Image Analysis System (Southern Microinstruments, Atlanta, GA and Bioquant Wild Leitz, Philadelphia. PA) (Thble 3). Before measurement, all instruments were calibrated against a single gray-level standard: the Kodak Greyscale Step Thblet. Using the Imagescan we also determined within-day precision and day-to-day precision (29.30) .
Specificity was determined on cells of the K562-NS line with specific IMPDH inhibitors (tiazofurin and ribavirin) and incubation mixtures without IMP substrate (CTRL1). Using a leukemic blast cell model (a population of a single type of cells with mean score of IMPDH activity from 0" to 3"). we assessed specificity against different substrates. For this experiment we used xanthosine monophosphate (XMP) and guanosine monophosphate (GMP), two substrates close to inosine monophosphate (IMP) in metabolic pathways leading to de novo purine synthesis (Table 4 ).
Assessment of I W D H Activity in Human Tumor Cell Lines
Four cell lines were selected for our study. First, to optimize our method and obtain reference values, we used the K562-NS cell line. This is a subclone derived 8 years ago from the original ATCC CCL 243 human erythroleukemia K562 cell line. This cell line model was selected because it responds consistently to IMP substrate stimulation, providing a narrow range of individual cell variation and stable reference values. The original K562 cell line has similar properties (16).
Another cell line, HL60, was used to compare our assay with standard biochemical assays. Dr. Daniel Wright (Department of Hematology, WRAIR, Washington, DC) kindly provided us with two clones of HL60, parent and derived. The parent ATCC CCL 240, human promyelocytic leukemia has a high level of biochemically measured IMPDH activity. The derived clone, HL60-M (label given by us) was produced in his laboratory by induction of maturation with dimethyl formamide (DMF) and is characterized by a low activity of this enzyme (31, 32) . 
Assessment of IMPDH Activity in Malignant CeZls from Dafferent Tumors
We assessed the IMPDH activity of blast cells in peripheral blood of patients with acute leukemia (13 cases) in relapse and undergoing remission induction, in whom blast cells made up more than 10% of the peripheral WBC count. Lacking examples of solid tumor cells exfoliated into tissue fluids (ascites, exudates), we used bronchial washings obtained from patients with bronchogenic carcinoma (six cases). Surgical biopsy specimens were obtained from patients with solid tumors (23 cases). The acute leukemia group included specimens from patients classified as acute myeloblastic leukemia (Ml, four cases), acute monomyeloblastic leukemia (M4, four cases), and acute lymphoblastic leukemia (L1, two cases and L2, three cases). All patients were in relapse, under treatment, and exhibited different degrees of response to therapy.
The solid tumor specimens included adenocarcinoma of the breast (17 cases), bronchogenic tumors (six cases), colon cancer (two cases), renal-cell adenocarcinoma (one case), epithelioma labii (one case), and thyroid cancer (one case).
Human tumor specimens were obtained from the Department of Pathology at the Institute of Oncology in Novi Sad and the University Clinical Center in Belgrade. We used only surplus peripheral blood specimens sent to the laboratory and pieces of fresh frozen tumor tissue material sent by surgeons for an ex tempore (frozen sections) histopathological diagnosis. The imprintlsmearing technique was used to prepare microscope slide specimens.
In Vitro Assessment of the IMPDH Pattern-targeted Drug Effect on K5 62-NS Ce ZZs
Conventional short (33)-and intermediate (subacute) (34)-term assays for in vitro assessment of drug toxicity/sensitivity on a model cell line (K562-NS) were used for assessment of the anti-tumor effect of drugs targeting IMPDH. Cell density, viability, and the morphological signs of maturation and damage were used as endpoint measures (20, (33) (34) (35) (36) (37) . They were compared with a change of IMPDH activity reported in EU and/or MS.
Tiazofurin and ribavirin are IMPDH inhibitors with limited (tiazofurin) and controversial (ribavirin) anti-tumor effects (38) (39) (40) (41) . We have previously compared the anti-tumor effects of tiazofurin and ribavirin with doxorubicin and cytarabine, using conventional assays (37, 42) .
Assessment of Drug-induced Alteration of Metabolic Pathways. An enzyme pattern-targeted chemotherapeutic agent should be able to enter the cell, undergo biotransformation into an active metabolite, and inhibit the target enzyme. Our assay provides an opportunity to assess in situ the residual activity of such a targeted enzyme. Details of the technique have been described elsewhere (35.36) . This technique can be used for preliminary screening of drugs for their activity against specific intracellular enzymes.
Assessment of Drug-induced Acute Cytotoxicity (Alteration of Membrane Integrity) of IMPDH-targeting Drugs. We have explored the sensitivity of K562-NS cells to acute exposure to tiazofurin and ribavirin using "pulse" exposure or short-term suspension culture (33.37) . Their effect against IMPDH was measured by the technique described above.
Assessment of Drug-induced Subacute Toxicity: Reduction of Cell Survival or Anti-proliferative Effect of the IMPDH-targeting Drugs. We have compared the inhibition of IMPDH activity with the anti-proliferative effects of tiazofurin, ribavirin, doxorubicin, and cytarabine. We used a conventional cell growth inhibition assay (34, 37) with aK562-NS cell line model instead of a primary tumor culture. The IMPDH assay was performed before and after it.
In all these experiments we have assessed the drug-induced reduction of intracellular IMPDH activity (IMPDH assay: EU and MS), the cell damage (morphology: criteria), cell killing (drug toxicity/cell viability assays: cell density, viability, and cytotoxicity index), and the inhibition of cell growing capacity (cell proliferation assay: cell density). Criteria for each of these endpoint parameters are presented in the description of Methods.
Reagents
Tiazofurin and ribavirin were kindly provided by ICN Galenika Pharmaceuticals (Belgrade, Yugoslavia). Adriamycin and cytosine arabinoside were kindly provided by the University Clinical Center (Belgrade, Yugoslavia). Other drugs and reagents were purchased from Sigma (St Louis, MO).
Marker of IMPDH Activity in Malignant Cell.
We have demonstrated the presence of IMPDH activity in cells of human tumor cell lines (K562, K562-NS, HL60, HL60-M), leukemic blast cells in peripheral blood of patients with acute leukemia (ALL, AML, AMML), malignant cells of several randomly selected surgical biopsy specimens (breast, colon, kidney, lung, skin, thyroid cancer), and malignant cells in bronchial washings (exfoliative cytology) of bronchogenic carcinoma (Figure 2 ; Table 2 ). Only morphologically intact and classified cells were used for evaluation and measurement.
IMPDH activity was seen as a granular, dark blue-violet intracellular deposit in positive cells (Figures 2A and 2C-2F) . The amount of marker present was related to the degree of enzyme activity.
HL60 cells, known to have high IMPDH activity as measured by biochemical methods, revealed in our assay a heavy granular deposit of formazan ( Figure 2E ). In contrast, HL60-M cells showed considerably lower activity than the parent cell line owing to induced maturation ( Figure 2F) (31) .
Assay Optimization
We optimized the method using the K562-NS cell line as a population of cells containing IMPDH at a relatively constant range amenable to standardization of reference values. Two important aspects of this optimization, the change of IMPDH activity relevant to individual components of the incubation mixture, and the effect of IMPDH inhibitors are presented in Table 4 and Figure 3 .
NBT alone was subject to spontaneous reduction, and some formazan may be produced without other components of the incubation mixture. This formazan precipitate could be increased by addition of NAD to the incubation mixture. PMS interfered with electron transport and the blank probe was stabilized (CTRL1). Addition of IMP activated IMPDH, producing more formazan (TEST) than in any experiment using a single agent or combination of agents ( Table 4 : Fl-F3, CTRL-1, and CTRL2). Potassium (K') ions increased formazan formation, but this effect was significant only if a complete incubation mixture, including IMP, was used. There was no additional formation with either GMP or XMP substrate instead of IMP.
The assay was optimized at the composition of incubation mixture as described for TEST. Tiazofurin and ribavirin, when incorporated into the TEST incubation mixture, induced a decrease of marker formation in a concentration dependent manner ( Table 4) .
According to these data, TEST seems to be a reasonable composition of reagents capable of providing an environment in which IMPDH can reduce IMP intracellularly, inducing a series of redox reactions, and producing a measurable intracellular deposit of formazan from NBT.
Reference Vaues for KS62-NS Cells
The IMPDH activity in K562-NS cells presented a well-defined image of dark-blue granular deposits of formazan scattered through the cytoplasm (Figure 2 ). Although the amount of this deposit differed from cell to cell, as a population the K562-NS cell line repeatedly demonstrated the presence of formazan in all morphologically acceptable cells ( Table 5) . Cells in mitosis were also positive. The formazan granules were distinct and their image was suitable for assessment with image analyzing instruments (Figures 2 and 4). This is the major advantage of this cell line, which we recommend as reference for our assay. Reference values for important measuring endpoints were established using Imagescan (Carl Zeiss) software, recently upgraded by us ( Figure 4 ; Table 5 ) .
Reliability of the Assay
Sensitivity. A microscopist may detect a single dark-blue granule of precipitated formazan inside a single cell. This is a threshold for visual detection. Otherwise, the assay sensitivity depends upon the sensitivity of the image analysis system (IAS). We used the Imagescan IAS (Carl Zeiss). At the IAS microscope magnification of x 132, green light of 540 nm, the maximal resolution of optical density was 1 gray level calculated against a standard calibration curve (35, 36) . This curve provides 64 distinct gray levels between total light (white, 2 5 5 gray levels) and total dark (black, 0 gray levels). Other IAS have appropriate calibration and sensitivity.
Precision. Imagescan is a high-precision instrument. Withinrun precision is 3% (Table 3) . Similar precision was found for two other IAS, SMI and Bioquant. Within-day precision and day-today precision with Imagescan are 4%. Subjective measurements and mean score also have significant precision. Within-run precision was measured by MS. The coefficient of variation for MS was CVMS = 10%.
Specificity. Specificity depends on the purity of the IMP substrate and other factors. The manufacturer of this substrate claims high purity. We have confirmed this specificity by measuring the residual IMPDH activity after exposure of cells to IMPDH-specific inhibitors and using two internal controls (Table 4) .
Comparison of formazan deposits in K562-NS cells and HL6O (high activity) and HL60-M (low activity) cells is presented on Table 2. These data were comparable to values obtained by the radiometric method using homogenized tissue culture cells (D. Wright, personal communication).
Morphological Signs Indicating Drug-induced Cell Change
All drugs used in this study (tiazofurin, ribavirin, doxorubicin, and cytarabine) under certain conditions induced morphological signs of cell transformation and damage. The number of cells affected and the degree of damage were dose-dependent. At equal concentrations, doxorubicin produced prominent cell damage. Tiazofurin produced the least amount of cell damage.
A few examples of tiazofurin-and ribavirin-induced damage of cells from two cell lines are shown in Figure 5 . Although criteria for description of this damage are available, they are still only qualitative. We used them for morphological identification of druginduced effects on either normal or malignant cells.
Intertumor Distribution of IMPDH Activity
A random selection of 29 solid tumors and 13 cases of leukemia exhibited unequivocal IMPDH positivity, although the degree of positivity differed from less than 100 mEU to 2000 mEU ( Table 2) .
All specimens obtained from randomly selected tumors (29 cases) were IMPDH-positive. However, the IMPDH positivity differed from disease to disease (breast, bronchogenic, and colon cancers being most strongly positive), from patient to patient, and even in a single patient. The variation observed among monoclonal populations of established cell lines (K562 and HL60, both clones) is due to serial assessment of IMPDH activity on cell-by-cell basis without consideration of cell morphology. In all other cases, the pathologist selected only morphologically intact cells that were classified as a single type of malignant cell.
Intratumor Distribution of IMPDH Activity Among Patients with Acute LeuRemia
Leukemic blast cells have distinct morphological characteristics used for subclassification. We selected our series of acute leukemia pa- Patients are subclassified according to the FAB classification. MI, acute myeloblastic leukemia with few azure granules in myeloblasts; M4. acute monomyeloblastic leukemia; L1. "children's" type of acute lymphoblastic leukemia; L2, "adult" type of acute lymphoblastic leukemia; CV, coefficient of variation; SD, standard deviation.
tients in groups according to the FAB classification and measured IMPDH activity only inside classified blasts (Table 6) .
We collected random specimens from patients undergoing induction of remission therapy. The percentage of blasts among other peripheral blood leukocytes varied in relation to their response to therapy. All blasts exhibited IMPDH activity, but at an amount below 1 EU. Differences in the degree of activity were noted among patients. A slight difference was noted between ALL and ANLL groups, suggesting that blasts with myelomonocytic characteristics might possess more IMPDH activity. However, patients with activity below the range acceptable for a positive result were recorded in all groups.
With this method we were not able to identify IMPDH activity in mature neutrophils.
Measurement of the Enzyme Pattern-Targeted Drug Effect on KS62-NS Cells
Assessment of Drug-induced Alteration of Metabolic Pathways. After 30-min exposure of K562-NS cells in situ to tiazofurin or ribavirin, distinct morphological damage occurred in the majority of cells. Cytoplasmic and nuclear swelling and fragmentation increased with drug concentration and were accompanied by a decrease of IMPDH activity in damaged cells (Figure 3 ). However, morphologically intact cells also demonstrated an intracellular tiazofurin-and ribavirin-induced inhibition of IMPDH. Control experiments showed that exposure of these cells to 1 mg/ml and 10 mg/ml of doxorubicin and cytarabine did not result in a signifi- cant measurable decrease of IMPDH activity. Morphological damage similar to that described above was also recorded as a response to the in vitro application of an LD5o dose of doxorubicin and cytarabine.
Acute Toxicity. Short-term incubation with tiazofurin, the "pulse" exposure, in a range of 0.01-15 mglml, was not sufficient to produce a change in either cell density or viability. A cytotoxicity index (CI) below 15 % can be considered only as being not substantial for tiazofurin action (Table 7) .
Similar experiments were performed with ribavirin. Both drugs induced a 20-30°h decrease in IMPDH activity without a measurable change of cell viability and/or morphological signs of cell damage.
Subacute Toxicity. After 72-h exposure of K562-NS cells to increasing concentrations of tiazofurin and ribavirin, a decrease in IMPDH activity, cell density (inhibition of proliferation), and a significantly lesser decrease in cell viability was recorded (Table 8 ). Doxorubicin and cytarabine used as controls induced about a 50% reduction of cell density and viability.
Discussion
We have described a novel method for intracellular measurement of IMPDH activity that may better help selection of patients sensi- tive to IMPDH enzyme pattern-targeted chemotherapy. Tumors with high intracellular IMPDH activity are likely to respond to IMPDH inhibitors. Furthermore, previous in vitro testing of the capability of an inhibitor to decrease IMPDH activity inside given tumor cells may also be a guide as to whether individual patients will respond to enzyme inhibition therapy.
Mode of Action and Measurement of Parameters
We determined the optimal experimental conditions (incubation mixture, temperature, pH, time of exposure) that would enable intracellular IMPDH to reduce an artificial substrate, IMP, XMP, thus stimulating a series of redox reactions including that of NAD, PMS, and finally NBT, resulting in the formation of reduced NBT (NBTH) or formazan. Because NBT may undergo autoreduction as well as reduction induced by different reduction capacities always present in cells, we optimized the reaction in such a way that the nonspecific dehydrogenase activity was minimized at the level of a small and controlled amount of formazan (CTRL1, control slide). The TEST slide was exposed to the same incubation mixture with the addition of IMP, a substrate specific for IMPDH. IMPDH alone catalyzed reduction of IMP to XMP, and the excess of H+ ions produced more formazan. We assume the following probable mode of action:
that may spontaneously differentiate into recognizable progenitors of granulocytes and monocytes, and this can be enhanced by DMSO (20) . Each laboratory should establish its own standards for PIcllu. and PITEST and calibrate them to present different activities of at least 1 EU.
Relation to Biochemical Methods
It is important to clarify the difference between biochemical and cytochemical methods. Our assay is the first cytochemical method available for the assessment of IMPDH activity inside malignant cells. Currently available biochemical methods are based on separation of selected cell populations, homogenization, and subsequent radiometric (11, 12, 33) or spectrophotometric (13,14) determination of enzyme activity. Radiometric methods were given preference because of their sensitivity and specificity (10) (11) (12) (13) (14) . This approach is satisfactory for monoclonal cell lines and leukemic blast cells. However, because of the well-known heterogeneity of tumor tissue specimens used for homogenization, these methods, providing only an average value of enzyme activity, cannot be considered sufficient to measure IMPDH activity inside tumor parenchymal cells, the actual target of the enzyme pattern-targeted chemotherapeutic agents. In addition, they are not adequate to demonstrate in clinical practice the important difference between a small population of high-positive cells and a larger population of low-positive cells. Individual differences in IMPDH activity among tumor cells also We do not advocate replacement of biochemical methods by cytochemical methods, but we do emphasize their difference and the fact that both should be available for assessment of tumor cell sensitivity to drugs before one decides to employ an IMPDH patterntargeted chemotherapy. Formazan (NBTH) precipitates at sites of enzyme activity. A microscopist can estimate the percentage of positive cells and the MS. All IAS can measure the area and density of digitized images, such as FRP and CELL, and can calculate SCEP and MCEP. We used these parameters to derive the assay measuring endpoints PI and EU (Figure 1) .
The most important parameters for application of the assay are the MS and EU. MS is a subjective estimate calculated according to Kaplow's recommendation for the subjective assessment of total neutrophil alkaline phosphatase activity (38) . By definition, EU measures the action that is specific only for IMPDH. Our data confirm this specificity ( Figure 3 ; Table 4 ). EU is a sensitive measure of the degree of drug-induced inhibition of intracellular enzymes.
Standard Reference
For reliability of this method, it is important to have a standard cell line, such as K562-NS, available to test nonspecific enzyme activity and IMPDH activity. This cell line was derived 8 years ago from the original ATCC CCL 243 K-562 cell line (16).
The original cell line has achieved widespread use as a highly sensitive in vitro target for cytotoxicity studies, and doxorubicininduced anti-tumor effects have been successfully studied with this model (37) . The new clone resembles the B population and blasts
Application and Prospects
Our assay gains in significance if the IMPDH inhibitors become part of chemotherapeutic protocols. Where we stand now? It is well understood that any of the IMPDH pattern-targeted anti-neoplastic drugs should be able to reduce tumor mass by two mechanisms: destruction of tumor cells (cytotoxic and anti-proliferative effects) and change of tumor cell growth pattem (induction of maturation). However, this is still only an assumption, based on many in vitro studies, pre-clinical trials but on few controversial clinical trials. We have used tiazofurin and ribavirin, two IMPDH inhibitors, and have studied their anti-tumor activity in vitro using conventional assays.
Tiazofurin, an investigational anti-neoplastic agent, is a recognized inhibitor of IMPDH activity and an inducer of K562 cell maturation. Ribavirin is another IMPDH-targeting drug with anti-viral activity, dubious anti-tumor activity, and some effect on maturation. Supporting literature gives much credit to tiazofurin as an anti-tumor agent (39, 40) . Tiazofurin (NSC 286193, 2-s-D-ribofuranosylthiazole-4-carboxamide), through its conversion to the active metabolite thiazole-4-carboxamide adenine dinucleotide (TAD), is a strong inhibitor of IMPDH (6, 8) . Its anti-tumor efficacy has been related to an interference with guanine nucleotide synthesis and to effects on induction of cell maturation (40, 41) .
In some clinical trials, tiazofurin caused a reversal to a chronic phase in patients with blast crisis of chronic granulocytic leukemia (7,8).
Tiazofurin was found to be a highly effective inhibiting agent of tumor metastases in mice (42). For use in humans, tiazofurin is still considered an investigational anti-neoplastic agent in the category of anti-metabolites (39,4346). However, tiazofurin induces cell death and cell maturation in several cell line models in vitro (43) (44) (45) (46) (47) (48) . The few reports related to the use of tiazofurin in patients with solid tumors have been disappointing, and reports indicating neurotoxicity of the drug have led to the Food and Drug Administration approval of this drug for clinical use in only a single circumstance: blast crisis of chronic myeloid leukemia. Recently, Weber (46) demonstrated that neurotoxicity was related to an unnecessary hyperdosage and suggested a less toxic and more effective drug regimen. This report offers new prospects for the use of tiazofurin and/or other similar nucleosides in human medicine; the impact of such a possibility on the field of cancer chemotherapy could be immense. We have demonstrated that tiazofurin, unlike doxorubicin, has no immediate cytotoxic effect, spares cytoplasm, has an anti-proliferative effect, and decreases cell density without significant change in cell viability. Tiazofurin appears to have only a slight maturational effect on K562-NS cells at concentrations used by us within 72 hr of exposure.
Ribavirin (l-~-~-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide) has been approved as the first synthetic, non-interferon-inducing, broad-spectrum anti-viral nucleoside (ICN-129; Virazole, Virazid). Ribavirin has a chemical structure similar to that of tiazofurin and it reduces IMPDH activity and induces the inhibition of in vitro growth of certain cell lines. It also exhibits some cell maturationinducing properties (9). Pre-incubation of purified IMPDH with ribavirin-5'monophosphate, the active form of ribavirin, enhanced its inhibitory effect in a time-dependent manner. This enhancement was further increased by the addition of TAD, suggesting a synergistic action (45). Currently available experimental data are controversial regarding the antitumor effects of this drug. It was our intention to test both drugs in parallel. We confirmed in vitro data indicating that ribavirin might also have anti-neoplastic activity.
We demonstrated IMPDH activity in all malignant cells studied. However, the level of this activity varied from a few mEU to 2000 mEU. Tiazofurin and ribavirin induced a concentrationdependent decrease in IMPDH activity. We believe that our preliminary data indicates the importance of measuring enzyme activity inside tumor parenchymal cells before any IMPDH patterntargeting drug is used for therapy of solid tumors. Further studies in this direction are warranted.
